habener glp 1 nobel prize GLP-1 agonists have transformed life for many people with type 2 TIME100 Health: Joel Habener, Dan

GLP-1 Receptor Agonist Market Key Takeaways Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer, Inc., Amgen, Inc., Innovent Biologics, Inc., PegBio Co., Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH Increasing prevalence of chronic diseases such as diabetes and obesity Increasing R&D activities for developing novel therapeutics Formulation advancements of oral GLP-1 receptor agonists Adverse effects associated with few GLP-1 agonist drugs Product recalls by market players With the increasing prevalence of diabetes and obesity, GLP-1 receptor agonists have become popular due to their effectiveness in glycemic control and weight reduction, offering a dual benefit in managing type 2 diabetes mellitus (T2DM)

(3) systemic GIPR-Ab, 5 mg kg 1

*Correspondence: Jinfu Zhang, [email protected]

It contains 620 mg of acetyl-L-carnitine clinically studied to support mitochondrial energy